Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astera Labs (ALAB) Cash & Equivalents (2023 - 2025)

Astera Labs' Cash & Equivalents history spans 3 years, with the latest figure at $167.6 million for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 110.7% year-over-year to $167.6 million, compared with a TTM value of $167.6 million through Dec 2025, up 110.7%, and an annual FY2025 reading of $167.6 million, up 110.7% over the prior year.
  • Cash & Equivalents for Q4 2025 was $167.6 million at Astera Labs, up from $140.4 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $696.1 million in Q1 2024, with the low at $45.1 million in Q4 2023.
  • Average Cash & Equivalents over 3 years is $213.9 million, with a median of $140.4 million recorded in 2025.
  • Biggest YoY gain for Cash & Equivalents was 110.7% in 2025; the steepest drop was 87.58% in 2025.
  • Tracing ALAB's Cash & Equivalents over 3 years: stood at $45.1 million in 2023, then soared by 76.4% to $79.6 million in 2024, then skyrocketed by 110.7% to $167.6 million in 2025.
  • Per Business Quant, the three most recent readings for ALAB's Cash & Equivalents are $167.6 million (Q4 2025), $140.4 million (Q3 2025), and $162.3 million (Q2 2025).